Popular GLP-1 weight loss drugs like Ozempic and Zepbound may help lower a woman’s risk for 14 types of cancer, a new study suggests.Researchers compared GLP-1 ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening ...

Glucagon-like peptide-1 receptor agonists may cut the risk of obesity-related cancer in patients being treated for diabetes and obesity.

Get Instant Summarized Text (Gist) GLP-1 receptor agonists are safe and effective for weight loss and glycemic control in adults with severe mental illness, including those on psychotropic medications ...

MET-097i, our most advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA that we are ... in a recent study, or Structure's ACCG-2671, which ...

Annual prevalence of GLP-1 RA use among US adults without diabetes increased from 0.1% in 2018-2021 to 0.4% in 2022, with an estimated 854,728 adults without diabetes taking these medications.

no use impacts the odds for outcomes following transplantation. Of the total cohort, 34 had GLP-1 RA use in the outlined time frame (mean time to initiation, 318 days), with 23 patients prescribed ...

Another benefit of GLP-1 receptor agonist (RA) use may be protection from persistent atrial fibrillation (Afib or AF) after ablation, according to a large Veterans Affairs database. New initiators ...

There were 396,963 eligible patients with T2D, of whom 33,858 were included in the GLP-1 RA versus the other glucose-lowering drug (GLD) cohort; 34,185 in the SGLT2i versus the other GLD cohort ...

Structure Therapeutics’ GSBR-1290 cut weight ... In June 2023, Pfizer discontinued the clinical development of another GLP-1-RA candidate, lotiglipron (PF-07081532), due to pharmacokinetic ...